Ignite Creation Date:
2024-05-05 @ 12:02 PM
Last Modification Date:
2024-10-26 @ 9:19 AM
Study NCT ID:
NCT00228553
Status:
COMPLETED
Last Update Posted:
2013-07-19
First Post:
2005-09-27
Brief Title:
Extension Study of the Safety and Efficacy of Armodafinil in the Treatment of Patients With Excessive Sleepiness
Sponsor:
Cephalon
Organization:
Teva Branded Pharmaceutical Products RD Inc
Study Overview
Official Title:
A 12-Month Open-Label Flexible-Dosage 100 to 250 mgDay Extension Study of the Safety and Efficacy of Armodafinil CEP-10953 in the Treatment of Patients With Excessive Sleepiness Associated With Narcolepsy Obstructive Sleep ApneaHypopnea Syndrome or Chronic Shift Work Sleep Disorder With an Open-Ended Extension Period
Status:
COMPLETED
Status Verified Date:
2013-07
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
No
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
A 12 Month Open-Label Flexible Dosage Extension Study of the Safety and Efficacy of Armodafinil CEP-10953 in the Treatment of Patients with Excessive Sleepiness Associated with Narcolepsy Obstructive Sleep ApneaHypopnea Syndrome or Chronic Shift Work Sleep Disorder
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None